@article{bourliere:hal-01134440,
TITLE = {Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).},
AUTHOR = {Bourli{\`e}re, Marc and Bronowicki, Jean-Pierre and de Ledinghen, Victor and H{\'e}zode, Christophe and Zoulim, Fabien and Mathurin, Philippe and Tran, Albert and Larrey, Dominique G and Ratziu, Vlad and Alric, Laurent and Hyland, Robert H and Jiang, Deyuan and Doehle, Brian and Pang, Phillip S and Symonds, William T and Subramanian, G Mani and Mchutchison, John G and Marcellin, Patrick and Habersetzer, Fran{\c c}ois and Guyader, Dominique and Grang{\'e},
Jean-Didier and Loustaud-Ratti, V{\'e}ronique and Serfaty, Lawrence and Metivier, Sophie and Leroy, Vincent and Abergel, Armand and Pol, Stanislas},
URL = {https://univ-rennes.hal.science/hal-01134440},
JOURNAL = {The Lancet Infectious Diseases},
PUBLISHER = {New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001-},
VOLUME = {15},
NUMBER = {4},
PAGES = {397--404},
YEAR = {2015},
MONTH = Mar, DOI = {10.1016/S1473-3099(15)70050-2},
KEYWORDS = {Adolescent ; Adult ; Aged ; Antiviral Agents / therapeutic use ; Benzimidazoles / therapeutic use ; Double-Blind Method ; Female ; Fluorenes / therapeutic use ; France ; Genotype ; Hepacivirus / classification ; Hepacivirus / genetics ; Hepacivirus / isolation \& purification ; Hepatitis C Chronic / complications ; Hepatitis C Chronic / drug therapy ; Hepatitis C Chronic / virology ; Humans ; Liver Cirrhosis / drug therapy ; Liver Cirrhosis / virology ; Male ; Middle Aged ; Placebos / administration \& dosage ; RNA Viral / blood ; Ribavirin / therapeutic use ; Sofosbuvir ; Treatment Outcome ; Uridine Monophosphate / analogs \& derivatives ; Uridine Monophosphate / therapeutic use ; Viral Load ; Young Adult},
HAL_ID = {hal-01134440},
HAL_VERSION = {v1},
}